Stock Comparison

MDLN vs PFE

Medline Inc vs Pfizer Inc

The Verdict

PFE takes this one.

MDLN

Medline Inc

0.1

out of 10

Distressed

Winner

PFE

Pfizer Inc

0.2

out of 10

Distressed

Head-to-Head

N/A

Market Cap

$150.6B

N/A

P/E Ratio

19.4

N/A

Profit Margin

12.4%

N/A

Return on Equity

8.7%

N/A

Debt-to-Equity

0.7

N/A - Risk assessment for a hypothetical public listing. As a private company, the risks are primarily operational and strategic, not investment-specific for public shareholders.

Overall Risk

Moderate

0.1

DVR Score

0.2

The Deep Dive

MDLN0.1/10

Medline Inc. (MDLN) remains a privately held company as of 2026-03-29. Therefore, the provided ticker, current price ($41.36), and market cap ($54.33B) are entirely hypothetical for a public entity. As such, traditional public market analysis for 10x growth potential within 3-5 years is not applicable. Even if Medline were to go public at this hypothetical valuation, achieving 10x growth to over $...

Full MDLN Analysis

PFE0.2/10

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...

Full PFE Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.